Moshe E. Gatt

3.9k total citations
113 papers, 1.3k citations indexed

About

Moshe E. Gatt is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Moshe E. Gatt has authored 113 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Hematology, 60 papers in Molecular Biology and 43 papers in Oncology. Recurrent topics in Moshe E. Gatt's work include Multiple Myeloma Research and Treatments (47 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (25 papers) and Protein Degradation and Inhibitors (23 papers). Moshe E. Gatt is often cited by papers focused on Multiple Myeloma Research and Treatments (47 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (25 papers) and Protein Degradation and Inhibitors (23 papers). Moshe E. Gatt collaborates with scholars based in Israel, United States and Spain. Moshe E. Gatt's co-authors include Ora Paltiel, Neta Goldschmidt, Irit Avivi, Galia Spectre, Giovanni Palladini, N. Luisa Hiller, Mala Mani, Ruth Stalnikowicz, Daniel R. Carrasco and Kenneth C. Anderson and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Moshe E. Gatt

101 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Moshe E. Gatt Israel	19	630	447	433	191	174	113	1.3k
Yaël C. Cohen Israel	19	389 0.6×	669 1.5×	537 1.2×	162 0.8×	211 1.2×	141	1.4k
Renée M. Y. Barge Netherlands	23	379 0.6×	504 1.1×	343 0.8×	139 0.7×	318 1.8×	44	1.5k
Randi Isaacs United States	22	588 0.9×	276 0.6×	582 1.3×	107 0.6×	217 1.2×	41	1.6k
Akiyoshi Miwa Japan	14	319 0.5×	517 1.2×	402 0.9×	175 0.9×	147 0.8×	79	1.1k
David Michonneau France	20	279 0.4×	439 1.0×	268 0.6×	111 0.6×	421 2.4×	82	1.2k
Masatsugu Tanaka Japan	24	349 0.6×	1.1k 2.3×	476 1.1×	263 1.4×	325 1.9×	196	1.9k
Jihyang Lim South Korea	19	264 0.4×	503 1.1×	244 0.6×	175 0.9×	269 1.5×	114	1.3k
Kazuo Sakashita Japan	20	450 0.7×	446 1.0×	246 0.6×	174 0.9×	386 2.2×	125	1.4k
Steve Schey United Kingdom	17	342 0.5×	651 1.5×	534 1.2×	280 1.5×	258 1.5×	45	1.4k
Adan Rios United States	15	235 0.4×	141 0.3×	465 1.1×	145 0.8×	382 2.2×	67	1.2k

Countries citing papers authored by Moshe E. Gatt

Since Specialization

Citations

This map shows the geographic impact of Moshe E. Gatt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Moshe E. Gatt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Moshe E. Gatt more than expected).

Fields of papers citing papers by Moshe E. Gatt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Moshe E. Gatt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Moshe E. Gatt. The network helps show where Moshe E. Gatt may publish in the future.

Co-authorship network of co-authors of Moshe E. Gatt

This figure shows the co-authorship network connecting the top 25 collaborators of Moshe E. Gatt. A scholar is included among the top collaborators of Moshe E. Gatt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Moshe E. Gatt. Moshe E. Gatt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Aumann, Shlomzion, et al.. (2025). First case report of talquetamab use in AL amyloidosis. Leukemia & lymphoma. 66(14). 2618–2623.

Vainstein, Vladimir, P. Milani, Giovanni Palladini, et al.. (2024). Belantamab Mafodotin in Relapsed/Refractory AL Amyloidosis: Real-World Multi-Center Experience and Review of the Literature. Acta Haematologica. 148(4). 419–426. 3 indexed citations

Aumann, Shlomzion, Vladimir Vainstein, Ariela Arad, et al.. (2024). DNMT3A, TET2, and ASXL1 (DTA) Mutations Are Associated with Thrombosis and Bleeding in Patients with Myeloproliferative Neoplasms. Blood. 144(Supplement 1). 3189–3189. 1 indexed citations

Golan, Talia, Ofer Purim, Danny Rosin, et al.. (2024). Multi-institutional validation survey on Belong.life's conversational artificial intelligence (AI) oncology mentor, "Dave.. Journal of Clinical Oncology. 42(16_suppl). e13596–e13596. 1 indexed citations

Bahlis, Nizar J., Rakesh Popat, Meral Beksaç, et al.. (2024). Efficacy of venetoclax-dexamethasone (VenDex) v pomalidomide-dexamethasone (PomDex) in patients (Pts) with t(11;14)-positive relapsed/refractory multiple myeloma [t(11;14)+ RRMM]: Phase 3 CANOVA study biomarker subgroup analysis.. Journal of Clinical Oncology. 42(16_suppl). 7510–7510. 5 indexed citations

Pick, Marjorie, Sharona Elgavish, Hadar Benyamini, et al.. (2023). Amyloidogenic light chains impair plasma cell survival. Haematologica. 108(12). 3359–3371. 2 indexed citations

Nachmias, Boaz, Svetlana Krichevsky, Moshe E. Gatt, et al.. (2023). Standardization of Molecular MRD Levels in AML Using an Integral Vector Bearing ABL and the Mutation of Interest. Cancers. 15(22). 5360–5360. 2 indexed citations

Vainstein, Vladimir, Batia Avni, Sigal Grisariu, et al.. (2023). Clonal Myeloid Dysplasia Following CAR T-Cell Therapy: Chicken or the Egg?. Cancers. 15(13). 3471–3471. 8 indexed citations

Kastritis, Efstathios, Giovanni Palladini, Paolo Milani, et al.. (2023). Venetoclax in Relapse/Refractory AL Amyloidosis—A Multicenter International Retrospective Real-World Study. Cancers. 15(6). 1710–1710. 16 indexed citations

10.

Kfir‐Erenfeld, Shlomit, Batia Avni, Sigal Grisariu, et al.. (2023). Safety and Efficacy of a Locally Produced Novel Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory Multiple Myeloma. Blood. 142(Supplement 1). 4852–4852. 1 indexed citations

11.

Aumann, Shlomzion, Boaz Nachmias, Dina Ben Yehuda, et al.. (2023). Risk factors and outcomes of COVID‐19 in adult patients with hematological malignancies: A single‐center study showing lower than expected rates of hospitalization and mortality. European Journal Of Haematology. 111(1). 135–145. 1 indexed citations

12.

Assayag, Miri, Batia Avni, Shlomit Kfir‐Erenfeld, et al.. (2023). Early lymphocyte collection for anti‐CD19 CART production improves T‐cell fitness in patients with relapsed/refractory diffuse large B‐cell lymphoma. British Journal of Haematology. 202(1). 74–85. 15 indexed citations

13.

Cohen, Yaël C., Daniel Morillo, Moshe E. Gatt, et al.. (2023). POSTER: MM-164 First Results From the RedirecTT-1 Study With Teclistamab (Tec) + Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 23. S226–S226. 1 indexed citations

14.

Cohen, Yaël C., Daniel Morillo, Moshe E. Gatt, et al.. (2023). MM-164 First Results From the RedirecTT-1 Study With Teclistamab (Tec) + Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 23. S478–S479. 1 indexed citations

15.

Kfir‐Erenfeld, Shlomit, Sigal Grisariu, Batia Avni, et al.. (2022). Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis. Clinical Cancer Research. 28(23). 5156–5166. 21 indexed citations

16.

Gatt, Moshe E., Adir Shaulov, Eirini Katodritou, et al.. (2020). Characteristics and outcome of multiple myeloma patients presenting with anaemia only: A retrospective multi-centre study. Leukemia Research. 101. 106498–106498. 2 indexed citations

17.

Gatt, Moshe E., Iuliana Vaxman, Tamar Tadmor, et al.. (2020). Daratumumab for relapsed AL amyloidosis—When cumulative real‐world data precedes clinical trials: A multisite study and systematic literature review. European Journal Of Haematology. 106(2). 184–195. 18 indexed citations

18.

Shaulov, Adir, Irit Avivi, Yaël C. Cohen, et al.. (2017). Gastrointestinal perforation in light chain amyloidosis in the era of novel agent therapy – a case series and review of the literature. Amyloid. 25(1). 11–17. 6 indexed citations

19.

Gatt, Moshe E., Kohichi Takada, Mala Mani, et al.. (2013). TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity. British Journal of Haematology. 162(2). 210–220. 24 indexed citations

20.

Mani, Mala, Daniel E. Carrasco, Yunyu Zhang, et al.. (2009). BCL9 Promotes Tumor Progression by Conferring Enhanced Proliferative, Metastatic, and Angiogenic Properties to Cancer Cells. Cancer Research. 69(19). 7577–7586. 151 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact